Category Medicine and Healthcare
Press Release
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership Read More
Press Release
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID Company completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVID REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q3 2025 financials and company updates; Click here to register Read More
Press Release
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment. Read More
Press Release
President Trumps Cannabis Decision Soon: From Hemp Shutdown to Pharmaceutical Clarity: MMJ Leads Federally Legal Cannabis Drug Development
"The federal hemp crackdown has created long overdue pharmaceutical clarity. MMJ is now the company advancing a fully compliant cannabinoid drug program under FDA and DEA oversight," noted Duane Boise, CEO MMJ International Holdings. "Drug development allows for no shortcuts. It demands consistency, validation, and adherence to federal law." Read More
Press Release
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by Preferred Stock Financing ~ Read More
Press Release
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - Read More
Press Release
Tom Brady 1/1 NFL Shield Autograph Card Hits Fanatics Collect Premier Auction Through Medical Care Technologies Inc. (OTC PINK:MDCE) Subsidiary Infinite Auctions
With 6-figure expectations this one of one 2009 Topps Unique Tom Brady card featuring a game-worn NFL Equipment patch and autograph is now live at Fanatics Collect's Premier Auction that ends Thursday, November 20, 2025 at 9:30 PM Eastern Time (EST). Read More
Press Release
Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians
Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy Network') and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030 Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid® to Galectovid 1 & 3 inhibitor Medical Food Galectovid® distribution agreement to Pharmacy Network & physicians Read More
Press Release
TRNR Reports Record Third Quarter 2025 Results with 139% YoY Growth; Reiterates 2025 Pro Forma Revenue Guidance of $80M+ To Be Driven by Completion of Sportstech Acquisition
Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1) Company Reports Record Quarterly Revenue of $4.8 Million; Net Loss and Loss per Diluted Share of $5.2 Million and $3.11; Quarterly Adjusted EBITDA Loss of $2.9 million, Due to Low Inventory Availability Sportstech Acquisition Expected to Close in 2025 Based on Key Closing Milestone Achievements Reiterates 2025 Pro Forma Revenue Guidance of more than $80 million and Fourth Quarter Profitability Guidance Read More
Press Release
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balance at September 30, 2025 Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time Read More
Press Release
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive Groundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID Read More
Press Release
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM Read More
Press Release
Federal HEMP Crackdown & Cannabis Court Rulings Confirm MMJ's Pharmaceutical Vision
As Congress and the courts reaffirm federal supremacy in cannabis-hemp regulation, MMJ International Holdings stands with a DEA licensed lab, two accepted FDA Investigational new drug applications, and a completed THC-CBD soft gelatin medicine-proving that true compliance, not state loopholes, defines the future of cannabis medicine. Read More
Press Release
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action. Read More
Press Release
Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure
Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market Read More
Press Release
CBD Life Sciences Inc. (CBDL) Secures Major Hemp Flower Order From Bronx Dispensary Smoking Scholars Amid Explosive Growth
With a staggering 1405.46% revenue surge since February 2024, CBDL continues its explosive expansion as Smoking Scholars places another major order in New York's $7.2 billion cannabis market. Read More
Press Release
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated Read More
Press Release
Federal Marijuana Crackdown Confirms the Future: DEA's Obstruction of MMJ Science Exposed as Congress Moves to Re-Criminalize the $30 Billion THC Gray Market
MMJ International Holdings stands as one of a few compliant, FDA regulated blueprint for cannabis medicine as a 37 state bipartisan AG coalition and sweeping new federal legislation once passed will eliminate "gas-station weed" and intoxicating THC beverages. Read More
Press Release
Medical Care Technologies Inc. (OTC PINK:MDCE) Marches Forward with Breakthrough Patent-Pending AI Healthcare Solutions using Smart Devices
A very unique multi-vertical health AI engine capable of early detection for mental health, wound infection, skin cancer, and disease risk-all through a smartphone Read More
Press Release
Watch the Marijuana Federal Action, Not the Speak: President Trump's Cannabis Decision Soon
With President Trump signaling openness to marijuana's medical benefits and 39 state attorneys general demanding a crackdown on unregulated hemp-derived THC, MMJ stands as the only federally compliant company prepared to deliver safe, pharmaceutical-grade cannabis treatments. As the nation moves toward a Federal Cannabis Reset, MMJ's FDA and DEA-aligned pathway offers the lawful, science-based solution America needs. Read More
Press Release
